Mavoglurant

Mavoglurant
Nazivi
	IUPAC naziv Metil (3aR,4S,7aR)-4-hidroksi-4-[(3-metilfenil)etinil]oktahidro-1H-indol-1-karboksilat
	Drugi nazivi AFQ056
Identifikacija
CAS broj	543906-09-8 ;
3D model (Jmol)	interaktivna slika;
ChemSpider	8102466;
ECHA InfoCard	100.219.728
PubChem C ID	9926832;
UNII	GT0I9SV4F6;
	SMILES O=C(OC)N3[C@@H]2CCC[C@@](O)(C#Cc1cccc(c1)C)[C@@H]2CC3; ; ; ; ; ;
Svojstva
Hemijska formula	C19H23NO3
Molarna masa	313,40 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Mavoglurant (AFQ-056) je eksperimentalni kandidat leka za tretman fragilnog X sindroma.^[3] On deluje kao antagonist metabotropnog glutamatnog receptora 5 (mGlu₅).^[4]

Mavoglurant razvija Novartis i trenutno je u fazi III kliničkih ispitivanja.^[3]^[5] U slučaju uspešnog ishoda ispitivanja, on će biti privi lek koji tretira poremećaju umesto simptoma fragilnog X sindroma.^[6]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ ^а ^б P. Cole (2012). „Mavoglurant”. Drugs of the Future. 37 (1): 7—12. doi:10.1358/dof.2012.37.1.1772147.
^ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA; et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease. 42 (3): 311—7. PMID 21316452. doi:10.1016/j.nbd.2011.01.022.
^ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K.; et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine. 3 (64): 64ra1. PMID 21209411. doi:10.1126/scitranslmed.3001708.
^ „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011.

Spoljašnje veze

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[Cole-3] а ^б P. Cole (2012). „Mavoglurant”. Drugs of the Future. 37 (1): 7—12. doi:10.1358/dof.2012.37.1.1772147.

[4] Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA; et al. (2011). „AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome”. Neurobiology of disease. 42 (3): 311—7. PMID 21316452. doi:10.1016/j.nbd.2011.01.022.

[5] Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K.; et al. (2011). „Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056”. Science Translational Medicine. 3 (64): 64ra1. PMID 21209411. doi:10.1126/scitranslmed.3001708.

[6] „AFQ056 drug improves symptoms in Fragile X patients: Study”. news-medical.net. 9. 1. 2011.

[3]

[4]

[1]

[2]

[5]

[6]